New Projects
Anderson Bell Christie is an architecture practice, based in Glasgow, that provide services to the social housing, healthcare, education and community sectors. They are working with the Department of Architecture at the University of Strathclyde to develop and implement a data driven design process for Zero Carbon Neighbourhoods, creating a place-based community-oriented solution to deliver holistic zero carbon living within the social housing sector.
AstraZeneca is a global, science-led biopharmaceutical business whose medicines are used by millions of patients worldwide. Their purpose is to push the boundaries of science to deliver life-changing medicines. The best way they can help patients is to be science-led and share this passion with the scientific, healthcare and business communities of the UK. Their KTP is to acquire the capability of using Pair Distribution Function (PDF) analysis using either synchrotron X-rays or lab source technology to gain quantitative insight into the structure of amorphous materials, where the structural coherence extends over only a few nanometres, rendering conventional solid form monitoring techniques ineffective.
R&B Distillers Ltd., formed in 2014, are artisanal distillers of whisky and gin. In 2017, they transformed Borodale House on the Inner Hebridean Isle of Raasay into a state-of-the-art distillery and hotel. They are working with the Department of Chemical and Process Engineering at the University of Strathclyde to embed capability in electrochemical engineering processes for energy storage and conversion, biomass energy, and clean fuel technologies, to develop a holistic energy plan for decarbonisation that can be retrofitted to their current distillery site, and implemented at future planned sites.
Renewable Parts Ltd. (RPL) is the leading independent supplier of parts for the UK’s wind turbine industry. They are working with the Advanced Materials Research Laboratory at the University of Strathclyde to embed capability in remanufacturing, metrology, assessment and evaluation of end-of-life-turbines, to enable development of a robust business development plan and process for whole turbine decommissioning and re-circulation of turbine parts for the renewables sector.
Target Healthcare Limited (THL) manufacture and supply a wide range of
pharmaceutical products, including generic, branded and unlicensed medicines. They are working with the Strathclyde Institute of Pharmacy and Biomedical Sciences to embed an understanding of formulation, characterisation, and analysis techniques, to develop platform capability, and enable creation of a robust framework for the assessment of shelf-life and stability of a range of aseptically prepared Monoclonal Antibodies (MABs) for patient use.
Vector Photonics’ PCSELs are the first, major break-through in semiconductor laser technology for 30 years. The company is a spin-out from one of the world’s leading academic groups in Photonics at the University of Glasgow. Its proprietary technology, developed since 2012, places Vector Photonics at the heart of the rapidly growing datacenter industry.
PCSELs (Photonic Crystal Surface Emitting Lasers) are low cost, robust with high speed and power. This combination of key characteristics gives them a huge advantage over present-day, commonly used VCSELs (Vertical Cavity Surface Emitting Lasers), which compromise wavelength range and power, and EEL lasers (Edge Emitting Lasers), which are high-cost and fragile. PCSELs have other advantages too. They emit light from the top surface, like VCSELs, making them easy to package and incorporate into PCBs and electronic assemblies. They are also made in a similar way to EELs, so existing, experienced, supply chain capability and capacity can be utilised.
Their KTP will embed expertise in testing and failure analysis methodologies to ensure that laser device products delivered to customers have undergone accelerated lifetime testing. This will drive commercial growth within the company and deliver a step change in Vectors manufacturing protocols.